Background: Teams are the principal vehicle in developing new drug development strategy and executing the tasks required to accomplish those objectives. The key research questions related to the measurement of team innovation performance in the branded pharmaceutical industry and identification of the drivers for optimal team performance outcomes. This project evaluated the key drivers for team innovation performance (defined as ''outcomes''). Team outcomes included new information creation, compression of development time, expansion of image, learning, capability development, growth satisfaction, and overall effectiveness. Methods: A total of 13 questions, with multiple subparts, as part of 7 key dimensions were adapted from previously validated scales. Eligible participants were those who were employed in a pharmaceutical R&D organization and were a member of a drug discovery and/or development team. Survey respondents were prompted to respond to the degree they agreed or disagreed using 5-to 7-point Likert-type scales. All analyses (reliability tests, factor analysis, and multivariate regression) were performed in IBM SPSS v22. Results: While good correlations individually existed between team outcomes (dependent variable) and tested independent variables (autonomy, coaching, climate, proactive personality, empowering leadership, and transactive memory systems [TMSs]), the best predictors identified through multivariate regression analysis were leader and peer coaching and TMSs. Conclusions: This research offers key insights for managers when forming and staffing teams. One is an emphasis on coaching. It is imperative for senior managers to assign individuals to teams who liaise with broader management that are capable of offering coaching and availability for team members to enhance their skills. This is particularly important in a growing hypercompetitive environment that is witnessing continuous strategic change. A second area of emphasis is on TMS, in an expertise-centered organization. As this is a central driver to team performance, it is imperative to improve adaptation skills of team members.
Introduction
Cross-functional project teams offer the structural and functional vehicle in the research and development (R&D) process, as they span various functional disciplines and continuum of time and space. These cross-functional teams are often composed of critical functional representatives and are chartered with the development of both the strategy and the tactical execution of predefined agreed upon deliverables. The members of the team represent their home functions but are accountable to the project leaders or liaisons that interface with broader organization. Each team is governed by a specific scientific management committee that endorses the strategy and monitors the outputs as the project team reaches a predefined milestone.
It is at this team level where an in-depth analysis of the core strategic issues-the ''what'' and the ''how'', happen.
Membership on teams is primarily assigned by the functional areas. The higher the assigned priority of the product in question, the greater is the need on the part of functional departments to provide their most knowledgeable and experienced representatives. Leadership of teams is similarly done, and project leaders could come from the assigned functions that are considered core on teams or from an independent senior leadership function. Thus, the type of teams usually conforms to Clark and Wheelright's typology. 1 Because of organizational diversity, the team is a good central point at which functions interact. The organizational proximity that occurs in teams allows for critical inputs to be shared much earlier in the process than may otherwise occur in the absence of these project teams. Moreover, these teams focus on milestone-oriented, highly focused, and time-sensitive tasks.
While teams are formed by senior management and have the flavor of top-down hierarchical systems, teams are intended to function autonomously, expected to be nimble, and expected to self-operate in flexible working cultures. In practice, however, there is large variability in how this is implemented. Depending on the nature of teams, priority of the project, and the complexity of the issues at hand, teams may function independently or with considerable oversight. The more experienced the membership, the greater the trust on the team. Thus, the transactive memory system (TMS) 2 is a critical determinant of outcomes. More recently, there has been increasing emphasis given to size of these teams and the increase in the use of subteams to pursue specialized tasks. However, in large companies that are often super specialized, there are often large pockets of subject matter expertise, causing teams to be traditionally large. Therefore, generation, communication, and sharing of tacit knowledge become a significant challenge. The sociocognitive aspects of knowledge sharing and learning become significant. Because teams do not control resources or budget and have to rely on functional departments for resources, there is often a tension between the team and the functions as well as with the oversight committees. Functions may elect to be more overbearing on teams, and that may result in teams not being empowered. Thus, team autonomy plays a role in team effectiveness. 3 Team decisions may be continually questioned, and there could be trust issues between the team and the functions, teams and their leaders, or the team leaders and the governance committees. Implicit leader behavior of managing the internal and external networks and effective boundary management will be key. 4 Team leadership, whether participatory or empowering or principally through coaching, and the climate under which the team operates influence team innovation and performance. 5 It is essential to fully understand the critical success factors that can contribute to team innovation and effectiveness in the pharmaceutical industry.
Two broad categories of teams, defined by scope and degree of innovation and creativity, are investigated in this project.
These are discovery and development teams operating within a large pharmaceutical R&D context. Discovery teams are those teams responsible for the design and execution of the strategy leading up to proof of concept in humans and can span the entire length from target identification and lead optimization until phase IIA of clinical development, and those teams are governed by the drug discovery and early development research committees. These teams can include heavyweight teams (eg, early development team) and functional (eg, drug substance and product team) teams. Development teams are those teams responsible for clinical development from phase IIB through registration and licensure of the product and life cycle management and are governed by late development research committee. These teams can include heavyweight teams (eg, product development team) and functional teams (eg, preliminary market formulation working group, clinical subteam, regulatory subteam, integrated development and supply teams, etc).
The following drivers for team innovation effectiveness (outcomes) have been specifically investigated, and their hypothesized relationships to outcomes shown in Table 1 
Methods

Survey Instruments
To test the hypotheses, a survey questionnaire testing specific dimensions that have been previously validated was used for rating by team members. The questionnaires were prepared in an electronic survey software (Qualtrics LLC) and distributed electronically to participants. Eligible participants belonged to a large pharmaceutical company, were members of a drug discovery or development team, and were mostly scientists, engineers, or physicians. Teams that have overall responsibilities of a set of activities within each defined scope of activity and level of the organization and team members responsible for defining the scope, developing a strategy, and executing the deliverables were eligible to participate in this survey. Team members may represent a cross section of the leadership in an R&D organization and may be members of any department. Each survey respondent was requested to select an active or recently completed project they were a part of as a member of the team. A total of 75 teams with approximately 500 to 600 members were contacted. To reduce survey fatigue, a single-stage survey was used. Because eligible teams need to be cross-functional in nature, they provide a heterogeneous mix of functional and overarching governance, operating in a wide scope of drug discovery and development value chain.
A total of 13 questions, with multiple subparts, as part of 7 key dimensions have been adapted from previously validated scales. These dimensions include team outcomes, team autonomy, leader and peer coaching, team climate, proactive personality, empowering leadership, and TMS. Survey respondents were prompted to respond to the degree he or she agreed or disagreed using 5-to 7-point Likert-type scales. The key variables including the reported internal consistency reliability 6 are summarized in Table 2 .
Statistical Analysis
All analyses were performed in SPSS version 22 (IBM Corp). These analyses included assessing the reliability of the scales used in the study, factor analysis, and multivariate linear regression for testing the various hypotheses. Statistical testing of the variables were assessed using a 2-tailed test at a significance level of .05. No multiplicity adjustment was made.
Results
Of the 75 teams contacted (composed of approximately 400-600 team members who form those teams), only 190 responded from 43 teams (57% response rate). Of these 190 team members, 80 members (42%) were from the discovery phase (from target identification to clinical proof of concept) and 110 (58%) were from the development phase (from clinical phase II through registration and life cycle management). These teams were staffed by scientists, engineers, and technologists, with a wide variation of first degrees to higher doctorates. Technology novelty is considered quite relevant in new product development and explains some of the uncertainty and ambiguity teams experience in product development. Nine percent of the respondents indicated there was no new technology involved in the teams, whereas 91% indicated various degrees of technology novelty. Interestingly, only 11% indicated that the technology in use was unproven or nonexisting at the start of the project. Eighty percent indicated that the technology was either incremental or preexisting in some form or another.
Using the Lynn and Akgun 13, 14 typology for innovation novelty, 31% indicated the innovation was incremental in nature, 19% indicated it was an evolutionary market project, 41% indicated it was an evolutionary technical project, and 9% indicated it was a radical innovation project.
Using Clark and Wheelwright 1 typology, 24% indicated the structure was a functional team grouped by discipline, 44% indicated the structure was a lightweight team with a liaison, 23% were part of a heavyweight team with a core group with a project leader, and 9% were on an autonomous team with full control of resources. These findings are in alignment with the broader organizational context, where there is less tolerance to risk and greater control of resources. The team player style using the Parker 15 typology showed that most members were collaborators, but only 8% indicated they were willing to challenge authority and be willing to take risks.
Validation of Reliability of the Scales
A reliability analysis was performed in SPSS to estimate the Cronbach's alpha for each of the dimensions of the survey study. Table 3 summarizes the values. The reliability analysis confirms very strong Cronbach alpha scores for the previously validated scales used in this study, with every scale showing >.90.
Factor Analysis
The method of principal component was used for extraction to determine eigenvalues, communalities, and factor-loading coefficients. All questions under each scale were evaluated separately, retaining components with significant eigenvalues (>1). The method of rotation chosen was direct oblimin, an orthogonal rotation method, because of expected correlations among factors inherent in behavioral and social science research. 16 The measures of appropriateness of the factor analysis included the Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy and the Bartlett test of sphericity. In all dimensions, KMO measures were 0.8 or higher, and the Bartlett test of sphericity was significant, indicating that there were correlations within the data set that were appropriate for factor analysis. An examination of communalities in each variable showed that all extracted values were acceptable, indicating reasonable correlation between items. In most cases, 1 to 3 factors accounted for a majority (80%) of the variability in all variables.
Multivariate Linear Regression
The prespecified hypotheses were tested using multivariate linear regression analysis in SPSS. Team outcome was identified as a dependent variable. Independent variables included team autonomy, leader and peer coaching, team climate, proactive personality, empowering leadership, and TMSs. Table 4 summarizes the descriptive statistics for the composite variables.
The means were all within the scale ranges of the individual range, with acceptable standard deviations. The sample size of 80 represents completers in survey responses, with missing data ignored. The test of significance of the model used analysis of variance. There are a total 79 (N-1) degrees of freedom. With 6 predictors, the regression effect has 6 degrees of freedom. The regression effect is statistically significant, indicating that the prediction of the dependent variable, outcome, is better than can be done by chance. Table 5 is a symmetric correlation matrix that summarizes the standard regression results, namely, the correlations of the variables (diagonal of the matrix is not shown). The prediction model was statistically significant, F(6, 73) ¼ 16.604, P < .001, and accounted for approximately 58% of the variance of team outcomes (R 2 ¼ .577, adjusted R 2 ¼ .542). The raw and standardized regression coefficients of the predictors along with their correlations with team outcomes are shown in Table 6 .
Team outcome was primarily predicted by higher levels of coaching and TMSs. Coaching received the strongest weight in the model, followed by TMSs. Coaching accounts for 9% of the variance of outcome, whereas TMSs accounts for 5.5% of the variance of outcome. Interestingly, climate and personality correlate substantially with outcomes and to lesser extent empowering leadership and autonomy, yet in the combination with other predictors are not significant predictors in the model. This is likely because their predictive work is being carried out by other variables in the analysis.
Therefore, the hypotheses that leader and peer coaching (H2) and TMSs (H6) are positively correlated with team outcome have been met. The remaining hypotheses were not met, although as indicated above, all others were positively correlated, albeit not statistically significant.
Discussion
Available research has been helpful in identifying key drivers of team effectiveness. 5, 17 However, each organizational context is unique and thus requires a contextually appropriate solution to enhancing team innovation and effectiveness.
In this project, teams are the principal vehicle of the delivery of the main output of pharmaceutical industry research and development, namely, innovation outputs of new drugs and new drug products. Contextually, therefore, team innovation and effectiveness performance is a principal feature of team outcomes. This is further measured as a function of information creation, time compression, image expansion, learning, growth satisfaction, overall effectiveness, and capability development. 7 For example, innovation and effectiveness in teams can be measured by new information creation that would result in intellectual property, development time to market and first mover advantage, new learning about a certain product or disease expertise, and successfully developing new drugs and line extensions. 18 While reasonably good correlations existed between the various independent variables and team outcomes, only 2 determinants turned out to be statistically significant predictors of team outcomes: leader and peer coaching and TMSs.
Baseline evaluations showed that much of the innovation performance in the organization were incremental in nature and used some variations of existing technology. These activities were supported by teams that were highly dependent on resources from outside of the teams to execute their work. In fact, only 9% belonged to an autonomous team with full control of their resources. A relative majority of the survey respondents belonged to teams that relied on the liaison figure on the team. Thus, it is not surprising that leader and peer coaching was a statistically significant predictor of team outcomes. A relative majority of survey participants identified themselves as collaborators, again bringing the context of coaching in positive light.
Because the pharmaceutical industry R&D apparatus is a knowledge-intensive organization, it is also not surprising that TMSs were also a key predictor of team outcomes. The collective network of knowledge and experience curves that exists in individuals and groups within the wider organizational context are essential in knowledge encoding, storage, and retrieval. 2, 19 A surprising finding in the project is the lack of statistical significance of proactive personality and empowering leadership as a predictor of team outcomes, despite a positive correlation existing between the independent variables and team outcomes. It helps to frame this finding within the wider organizational context. A diagnostic interview conducted with senior leadership in the company revealed that the organization has a risk-averse culture. Part of risk-averse culture relates to decisions on funding and milestone movements of projects to be tightly orchestrated by senior leadership, which could mean that a culture of empowerment may either not exist or be appreciated as a positive attribute. In such a case, this may mean that senior leadership is unwilling to relegate decision rights to teams and may partly explain why these variables were not a significant predictor for team outcomes. However, it is also a possibility that there may be collinearity between these 2 variables and the peer and leader coaching, which was a significant predictor, wherein their predictive work is being accomplished by peer and leader coaching in the multivariate linear regression model. A second surprising finding in this study was that team autonomy was not statistically significant as a predictor of team outcomes. This is contrary to an extensive body of published literature, which indicates that team autonomy strongly correlates with team performance (reviewed in Cohen and Bailey 5 ). However, a key underlying assumption is that autonomy might depend on the degree of task interdependence. Langfred 20 suggested that there is an optimal level of combination of individual and team autonomy that is highly dependent on the level of task interdependence in a given team. For example, autonomous teams that are tasked with highly interdependent activities may have an appropriate level of infrastructure (ie, coordination and cohesiveness) already in place that contributes to a positive relationship with team outcomes. However, there may be situations in which autonomous teams might incur additional penalty, such as coordination costs, which may negate the value team autonomy may have as a significant predictor of team performance. This is further supported by the work of Cummings, 21, 22 which shows that autonomous teams that are less interdependent may actually result in lower performance than teams that perform highly interdependent tasks. Therefore, it is possible that a part of the reason why team autonomy was not significant in this study may relate to the presence of significant coordination costs that may have existed in the teams. Because only a very small number of survey participants identified themselves as members of autonomous teams, it is not clear whether a higher sample size would have yielded a more predictable relationship.
Another surprising finding was that team climate was also not statistically significant as a predictor of team outcomes. This finding contrasts the findings in the literature, which argue that climate for innovation is a significant precondition to managing work teams involved in knowledge intensive enterprises. 8, 9 It is worthwhile to point out that there were considerable change events in the wider organizational context that created restlessness in the organization. Such activities may have caused a disruption in the overall climate and the boundary conditions under which these teams operated and could explain why team climate was not a statistically significant predictor of team outcomes.
The following sections further discuss the 2 hypotheses that were met in greater detail.
Leader and Peer Coaching
The leader and peer coaching instrument used in this study was a subscale of the team diagnostic survey 4 and included such characteristics as focus of leader's attention, coaching availability, task-focused peer and leader coaching, operant coaching, and interpersonal peer and leader coaching. When reviewing the wider organizational context, it is clear that the company had progressed through multiple layers of strategic and transformational change. Thus, a principal role of the leader and peer in a team is sense making 23 and navigating through evolving emergent change while maintaining focus on team tasks and deliverables-an adaptive change, as a failure to do so could be disruptive to the team and its subtle internal dynamics. 24 Existing committees were decommissioned, and new committees were formed within the wider organizational context. The team members viewed and counted on their leader as well as other members of the team to make sense of the changes around teams and still carry out tasks and deliverables to their overall satisfaction as well as those of their immediate management. The core roles a leader plays include coaching, developing, and mentoring the team, and this has been shown to have a positive impact on team performance. 4, 25, 26 The leader ensures that each team member has adequate skills and knowledge to perform that role, and there is sufficient emphasis on training and coaching of the team members. 27, 28 Because the leader on the teams investigated in this project were largely those who related with other team members in a liaison role and not as senior leadership, any sense-making behavior leaders exercised was likely not viewed as intrusive by team members. 29 Another role leaders have is providing feedback to team members, which helps in increasing team learning behavior. In this regard, the findings in this study are consistent with those examined by Gibson and Vermeulen, 30 with the exception that the leaders on teams examined here were not in a formal contract with team members as to their performance management. Notably, only 9% of survey participants identified themselves as members of autonomous teams, whose leaders have direct accountability to team performance and resource assignments.
TMSs
The TMSs scale instrument evaluated specialization, credibility, and coordination. 12 The core aspect of this instrument relies on capturing team members' collective expertise, a fundamental element to a knowledge industry such as the pharmaceutical industry. Knowledge in the pharmaceutical industry is a core competency, critical to an organization's sustained competitive advantage. 31 Knowledge resource is an inherent dynamic capability, the intangible synergy that ensues when a group of scientists, physicians, and engineers collaborate to solve tangible medical need problems, a requisite for new drug product development. 32 TSM was a statistically significant predictor of team outcomes. This comes as no surprise given the knowledgeintensive nature of the industry, but it is more strongly relevant given the current organizational context. The teams surveyed in this study witnessed change events that resulted in significant disruption of knowledge activities (eg, as a result of reorganizations and/or mergers and acquisitions), including a mix of planned separations and unintended employee turnover, and elimination of redundant sites. Thus, the knowledge transfer aspect from one project team to another was a significant consideration. Managing that knowledge transfer with minimal loss of expertise was a key organizational goal.
Wegner 2 defines TMS as ''the cooperative division of labor for learning, remembering, and communicating relevant team knowledge.'' (p186) Whereas Wegner 2 originally intended to apply TMS to long-tenured employee groups, tenure is not necessarily the principal component of TMS. Rather, the intangible undefined synergy that exists in collective foresight during problem solving in group creativity is also an inherent feature of TMS. [33] [34] [35] Lewis 12 defined a TMS as the ''active use of transactive memory by 2 or more people to cooperatively store, retrieve, and communicate information.'' (p588) Both Wegner 2 and Lewis 12 underscore the cooperative cognitive systems that describe the intangible synergy in teams. TMS helps understand how effective teams apply based on known knowledge. TMS was a good predictor of team outcomes, and implicitly, this means that members of higher-performing teams specialize in different but complementary domains such that there is a higher-order task-specific knowledge applied to defined tasks. Another valuable insight gained is when staffing new teams; the more the complementarity of the expertise, the greater likelihood there is to develop TMS rapidly.
Other authors point out that the TMS is a repository of knowledge that transcends teams, to the wider organizational context. 36 However, the teams are tightly integrated within the broader organizational context, at least in the sample examined in this study, so it is assumed that team memory is a good surrogate of organizational memory. This assumption may be limited in cases in which the TMS is tightly linked to a mass group of departing employees, and the project team is then replaced as a whole. The work of Lewis et al 37 suggests that although group performance may vary between partially intact groups and intact groups if there is not an adaptation that occurs to correct inefficient TMS processes.
Conclusions
This research offers key insights for managers when forming and staffing teams.
One emphasis is on coaching. It is imperative for senior managers to assign individuals to teams who liaise with broader management that are capable of offering coaching and availability for team members to enhance their skills. This is particularly important in a growing hypercompetitive environment, which is witnessing continuous strategic change. Thus, a capable leader is one who provides coaching to the team members as well as helps them reach their growth potential as well as skills that will help with adapting to a continuously changing organizational context. The leader also favorably enables peer coaching. Importantly, the leader should have interpersonal skills that are not viewed as intrusive to team psyche and dynamics. Preferably, a team member who has been on the team as a peer and has evolved leadership skills, and who has gained the wider trust by peers, should be considered as a team leader.
A second area of emphasis is on TMSs. As this is a central driver to team performance, it is imperative to improve adaptation skills of team members. Particularly in cases in which there is anticipated to be a disruption to team membership, effort would need to be given to preserve the inner core of the team so that there is sufficient time available for learning by a new team member. Complete reconstitution of a team would be considered disruptive to TMS processes and thus preferable to avoid.
Limitations and Future Research Directions
One of the limitations of this study was the relatively small sample size. While the response rate was satisfactory, samples were drawn from a single large pharmaceutical company to ensure a single-frame organizational context. A relative majority of the survey participants identified with incremental innovation and technology novelty, precluding subset analysis between teams that focused on incremental and radical innovation. Although the study yielded valuable insights on drivers of team outcomes, this precluded more sophisticated analysis including path dependencies and subset analysis of the various dimensions as a function of team structure, innovation type, and technology novelty. One future research direction would be to study the team outcomes in a large diversity of pharmaceutical enterprises, of varying firm size and organizational context.
Because the leaders on the teams investigated in this project were largely those who related with other team members in a liaison role and not as senior leadership inherent in autonomous teams, whether some of the leader behavior was considered intrusive by team members could not be studied. 29 Thus, a second possible future research direction would be to study the role of senior leaders as team leader, where there is at least a gap of 3 to 4 managerial-tier level differences between leaders and team members.
As indicated above, because the sample size was not large enough to provide balance to the type of team structures, no attempt was possible to relate how TMSs operate in teams of differing team structures. A third aspect for future research on TMSs relates to complete reconstitution of group membership and how that affects team outcomes. This is particularly applicable to mergers and acquisition situations, in which a target company is subsumed in the acquirer company infrastructure, there is a near complete loss of talent either through voluntary or involuntary separations, and there is little to no institutional memory on projects.
A potentially fourth area for future research is to investigate team outcomes longitudinally with 2-stage surveys, at more than 1 snapshot of time. There are stage-gate milestones as the drug candidate moves from one phase to another (eg, discovery to development), and there is a natural transition between one type of team to another. Because the pharmaceutical industry is a slow innovation industry, in which the average time span from target identification to marketing can range from 10 to 15 years, 38 such a longitudinal study would have introduced considerable variability including but not limited to business model changes and personnel changes over time.
A final avenue of future research relates to the role of within-team competition in contributing to team knowledge sharing. This aspect was not studied in this project and is worth further study, partly because there is some degree of inherent competition within teams in knowledge-intensive organizations and partly because there are contradictory data in the literature that relate to how significantly affected team performance would be. 39 
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